医学
多发性骨髓瘤
重症监护医学
不利影响
疾病
来那度胺
肿瘤科
内科学
耐火材料(行星科学)
Carfilzomib公司
伊扎莫布
天体生物学
物理
作者
Abdul Hamid Bazarbachi,Rama Al Hamed,Florent Malard,Jean‐Luc Harousseau,Mohamad Mohty
出处
期刊:Leukemia
[Springer Nature]
日期:2019-08-27
卷期号:33 (10): 2343-2357
被引量:118
标识
DOI:10.1038/s41375-019-0561-2
摘要
Most patients with relapsed/refractory multiple myeloma (RRMM) have been treated with drug combinations including a proteasome inhibitor (PI) and/or an immunomodulatory drug (IMiD). The goal of therapy for such patients is therefore to achieve disease control with acceptable toxicity and patient-defined decent quality of life. Physicians face a difficult task not only deciding who to treat, but also when to treat and how to treat, utilizing knowledge of previously administered therapies, patient comorbidities, potential adverse events, and patient wishes to make such a critical decision. New drugs and combination regimens are continuously underway thus broadening the options for therapy and giving way to a more individualized approach for patients with RRMM. The integration of novel agents into the treatment paradigm has shifted the perception of multiple myeloma (MM) from an incurable, fatal disease to a manageable, chronic one. This comprehensive review addresses the results and challenges posed by many of the newer agents for the treatment of RRMM. It attempts to propose a universal strategy for optimal therapy decision-making thus answering three simple fundamental questions-when to treat, how to treat, and how long to treat for.
科研通智能强力驱动
Strongly Powered by AbleSci AI